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Abstract: Background: Remarkable deregulation of several microRNAs (miRNAs) is demonstrated
in cutaneous melanoma. hsa-miR-193a-3p is reported to be under-expressed in tissues and in plasma
of melanoma patients, but the role of both miR-193a arms in melanoma is not known yet. Methods:
After observing the reduced levels of miR-193a arms in plasma exosomes of melanoma patients,
the effects of hsa-miR-193a-3p and –5p transfection in cutaneous melanoma cell lines are investigated.
Results: In melanoma cell lines A375, 501Mel, and MeWo, the ectopic over-expression of miR-193a
arms significantly reduced cell viability as well as the expression of genes involved in proliferation
(ERBB2, KRAS, PIK3R3, and MTOR) and apoptosis (MCL1 and NUSAP1). These functional features
were accompanied by a significant downregulation of Akt and Erk pathways and a strong increase
in the apoptotic process. Since in silico databases revealed TROY, an orphan member of the tumor
necrosis receptor family, as a potential direct target of miR-193a-5p, this possibility was investigated
using the luciferase assay and excluded by our results. Conclusions: Our results underline a relevant
role of miR-193a, both -3p and -5p, as tumor suppressors clarifying the intracellular mechanisms
involved and suggesting that their ectopic over-expression could represent a novel treatment for
cutaneous melanoma patients.
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1. Introduction
Cutaneous melanoma, a malignant tumor arising from melanocytes, is the most aggressive
and fatal form of skin cancer with increasing incidence worldwide over the past several decades [1].
Targeted therapy and immunotherapy have considerably improved the outcome of advanced melanoma
patients, but resistance and toxicity, as well as incomplete therapeutic response, often arise [2–4].
Therefore, melanoma research still needs both to develop other treatments and associations, which can
prolong survival, and to identify biomarkers to early and accurately identify non-responding patients
or patients who are resistant to such treatments.
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To overcome these unmet clinical needs, molecular mechanisms involved in melanoma
development and progression need to be deeply investigated.
MicroRNAs (miRNAs or miRs) are short non-coding RNAs acting as master regulators of cellular
processes through the simultaneous modulation of the expression levels of hundreds of mRNAs.
Therefore, miRNAs are pleiotropic modulators of a wide array of biological processes, including
proliferation, differentiation, apoptosis, and development, influencing cell destiny [5–9]. The ability of
miRNAs to simultaneously silence multiple targets makes their transcriptional modulation of great
interest as a novel pharmacological strategy in cancer treatment [9,10], where a single pathway of
resistance leads to therapy failure [11].
Deregulation of miRNAs in cancer and cutaneous melanoma is reported in both tissues and
biofluids, where several miRNAs emerged as oncogenes or tumor suppressors with key functions
in carcinogenesis and cancer progression [12]. In particular, Homo sapiens (hsa)-miR-193a caught
our attention because its role in cutaneous melanoma has only partially been explored [13,14].
MiR-193a is a member of the miR-193 family including miR-193a, miR-193b, and miR-193c. MiR-193a
coding gene, named MIR193A, is located on human chromosome 17q11.2 in an active transcriptional
region. During miRNA biogenesis, two mature miRNAs (arms) are generated from pre-miR-193a:
miR-193a-3p (sequence: AACUGGCCUACAAAGUCCCAGU, accession number: MIMAT0000459) and
miR-193a-5p (sequence: UGGGUCUUUGCGGGCGAGAUGA, accession number: MIMAT0004614).
Both miR-193a arms are expressed in all normal tissues in physiological conditions [15,16] and
they are reported to be deregulated in different types of human cancers, in which they can act
as tumor suppressors or oncogenes. In detail, in several tumor tissues, miR-193a-3p appeared
downregulated and showed tumor-suppressive properties [17–24]. Conversely, Yi and colleagues
reported a significant upregulation of miR-193a-3p in esophageal squamous cell carcinoma tissues,
where it acts as an oncogene [25]. Regarding melanoma, the down-expression of miR-193a-3p
in melanoma tissues is already reported [13,26,27]. The miR-193a-5p expression in melanoma
cells and tissues has been studied [26,27] and reports show it as downregulated in various cancer
types [21,28–32] but also upregulated in prostate cancer tissues [33]. As far as circulating levels is
concerned, circulating miR-193a-3p has been found deregulated in several types of tumors [34–36],
while circulating miR-193a-5p has been only reported upregulated in plasma of hepatocellular
carcinoma [37]. In melanoma, circulating miR-193a-3p was at lower levels in the plasma of patients
at all stages of disease compared to healthy donors [14], whereas the circulating expression levels of
miR-193a-5p in biofluids of melanoma patients have not been investigated yet.
Concerning their activity in cancer cells, miR-193a -3p and -5p were observed to silence several
targets such as Kirsten rat sarcoma viral oncogene homolog (KRAS) [38,39], Erb-B2 receptor tyrosine
kinase 2 (ERBB2) [40], phosphoinositide-3-kinase regulatory subunit 3 (PIK3R3) [21], mechanistic target
of rapamycin kinase (mTOR) [21], myeloid leukemia cell differentiation (MCL1) [17], and nucleolar
and spindle associated protein 1 (NUSAP1) [38]. All these targets are considered to be associated with
carcinogenesis or cancer progression [41–44].
In a pilot study, we verified the occurrence of reduced levels of both miR-193a arms expression
in exosomes plasma-derived from advanced melanoma patients and healthy subjects. The present
study evaluated the tumor suppressor activity of miR-193a-3p and -5p in cultured melanoma cells
from primary tumor and metastasis.
2. Results
2.1. Down-Expression of Exosome-Derived miR-193a Arms in Plasma of Melanoma Patients
Patient characteristics of 11 stage IV melanoma patients, enrolled from January 2015 to February
2016, are reported in Table 1. The median ages of the melanoma patients and healthy volunteers were
60 and 55 years, respectively.
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Both miR-193a-3p and -5p showed a significant down-expression (p< 0.05 and p< 0.01, respectively)
in melanoma patients compared to healthy controls (Figure 1).
Table 1. Characteristics of the study population.
Variable %
Sex
Male 72.7
Female 27.3
Breslow thickness
<0.75 mm 0
>0.75 mm 100
Clark level
I-II-III 0
IV 18.12
V 81.2
Ulceration
Present 81.8
Absent 18.2
LDH levels
Normal 100
Elevated 0
Patient condition
Alive with stable disease 54.5
Alive in progression 27.3
Dead 18.2
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Figure 1. Expression levels of exosome-derived miR-193a in plasma samples. Relative expression of 
miR-193a-3p (A) and miR-193a-5p (B) in stage IV melanoma patients (IV) and healthy subjects (Ctrl). 
Statistical analysis was performed using Student’s t-test (* p < 0.05, ** p < 0.01). 
2.2. Ectopic over-Expression of miR-193a Arms Inhibits Cell Viability 
The ectopic over-expression of miR-193a-3p and miR-193a-5p at 10 nM in the three melanoma 
cell lines: A375 (ATCC® Manassas, VA, USA CRL-1619, from primary cutaneous melanoma), MeWo 
(ATCC® HTB-65, from lymph nodal cutaneous melanoma metastasis) and 501Mel (from not better 
specified metastatic cutaneous melanoma) caused a significant time-dependent inhibition of cell 
viability, compared to the correspondent scrambled miRNA transfected cells. 
Decrease in cell viability was significant after 72 h and was maintained until 120 h 
post-transfection in all three cell lines (Figure 2). 
Figure 1. Expression levels of exosome-derived miR-193a in plasma samples. Relative expression of
miR-193a-3p (A) and miR-193a-5p (B) in stage IV melanoma patients (IV) and healthy subjects (Ctrl).
Statistical analysis was performed using Student’s t-test (* p < 0.05, ** p < 0.01).
2.2. Ectopic Over-Expression of miR-193a Arms Inhibits Cell Viability
The ectopic over-expression of miR-193a-3p and miR-193a-5p at 10 nM in the three melanoma
cell lines: A375 (ATCC® Manassas, VA, USA CRL-1619, from primary cutan ous melanoma),
MeWo (ATCC® H B-65, from lymph nodal cutaneous melanoma metastasis) and 501Mel (from not
better specified metastatic cutane us melanoma) caused a significant t me-dependent inhibition of cell
viability, compared to the corre pondent scrambled miRNA transfected c lls.
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Decrease in cell viability was significant after 72 h and was maintained until 120 h post-transfection
in all three cell lines (Figure 2).
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Figure 2. Ectopic over-expression of miR-193a arms reduces melanoma cell viability. Cell viability 
was analyzed by Neutral Red assay at different time points in A375 (A), MeWo (B), and 501Mel (C) 
cell lines. Data are representative of three independent experiments ± SD performed in triplicate. 
One-way ANOVA followed by Dunnett’s multiple comparisons test was performed; * p < 0.05, ** p < 
0.01, *** p < 0.001 compared to the corresponding control. 
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several biological processes including “mitogen-activated protein kinase (MAPK) cascade” (12 
genes, p < 0.05), “activation of MAPK activity (7 genes, p < 0.05), “positive regulation of cell 
migration” (10 genes, p < 0.05), “positive regulation of cell cycle” (5 genes, p < 0.01), and “positive 
regulation of cell proliferation” (23 genes, p < 0.01) (Figure 3A). 
To determine whether the tumor suppressor activity suggested by GO and seen with ectopic 
over-expression of miR-193a arms was associated with the downregulation of some of the targets 
previously identified, we analyzed the expression of selected mRNA transcripts in the three 
melanoma cell lines.  
All the chosen targets of miR-193a-3p and -5p are not only predicted by bioinformatics tools but 
were also validated and expressed in melanoma cells (as reported in The Human Protein Atlas). 
Indeed, Fan and colleagues validated KRAS as a target of miR-193a-3p [45]; Yu and colleagues 
validated PIK3R3 and mTOR as targets of miR-193a-5p [21]. ERBB2 is a validated target of both arms 
[40,46,47]; NUSAP-1 of miR-193a-5p [48] and MCL-1 of miR-193a-3p [49,50]. 
Over-expression of miR-193a-3p downregulated the transcriptional expression levels of KRAS, 
EBBB2, and MCL1. Over-expression of miR-193a-5p downregulated the transcriptional expression 
levels of ERBB2, PIK3R3, MTOR, and NUSAP1 (Figure 3B–D). 
Figure 2. Ectopic over-expression of miR-193a arms reduces melanoma cell viability. Cell viability was
analyzed by Neutral Red assay at different time points in A375 (A), MeWo (B), and 501Mel (C) cell
lines. Data are representative of three independent experiments ± SD performed in triplicate. One-way
ANOVA followed by Dunnett’s multiple comparisons test was performed; * p < 0.05, ** p < 0.01,
*** p < 0.001 compared to the corresponding control.
2.3. Bioinformatic miRNA Pathway Analysis and e e ownregulation
To an lyze the possible biological meaning f t e ect ic er-expression of miR-193 arms, all
predicted target genes of miR-193a arms obtained fro the TargetScan database (Tables S1 and S2 in
Supplementary Materials) were imported into DAVID to determine GO biological processes (BP).
GO analysis revealed the involvement of miR-193a arms in cancer by negatively affecting several
biological processes including “mitogen-activated protein kinase (MAPK) cascade” (12 genes, p < 0.05),
“activation of MAPK activity (7 genes, p < 0.05), “positive regulation of cell migration” (10 genes,
p < 0.05), “positive regulation of cell cycle” (5 genes, p < 0.01), and “positive regulation of cell
proliferation” (23 genes, p < 0.01) (Figure 3A).
To determine whether the tumor suppressor activity suggested by GO and seen with ectopic
over-expression of miR-193a arms was associated with the downregulation of some of the targets
previously identified, we analyzed the expression of selected mRNA transcripts in the three melanoma
cell lines.
All the chosen targets of miR-193a-3p and -5p are not only predicted by bioinformatics tools but
were also validated and expressed in melanoma cells (as reported in The Human Protein Atlas). Indeed,
Fan and colleagues validated KRAS as a target of miR- 93a-3p [45]; Yu and colleagues validated
PIK3R3 and mTOR as targets of miR-193a-5p [21]. ERBB2 s a validated target of both arms [40,46,47];
NUSAP-1 of miR-193a-5p [48] and MCL-1 of miR-193a-3p [49,50].
Over-expression of miR-193a-3p downregul ted the transcriptional expression lev ls of KRAS,
EBBB2, and MCL1. Over-expressio of miR-193a-5p downregulated the transcriptional expression
levels of ERBB2, PIK3R3, MTOR, and NUSAP1 (Figure 3B–D).
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-5p was measured by RT-qPCR. Data are normalized to β-actin and control mimic-transfected cells. 
Data are representative of three independent experiments ± SD performed in triplicate. Statistical 
analysis was performed using Student’s t-test (* p < 0.5, ** p < 0.01, compared to the corresponding 
control.) 
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melanoma cells, inducing cell proliferation and survival. Therefore, we analyzed the ability of 
miR-193a arms to modulate the protein expression level of B-Raf and the phosphorylation levels of 
Erk 1/2 and Akt 1/2/3. 
Both miR-193a-3p and miR-193a-5p over-expression induced a significant decrease in B-Raf 
levels and a decrease in phosphorylation of Akt 1/2/3 and Erk 1/2 proteins in all melanoma cell lines 
(Figure 4).  
Noteworthily, miR-193a -3p and -5p decreased the phosphorylation of Erk 1/2 without altering 
the total protein levels. The observed decrease of B-Raf protein is in line with the reduced activation 
of Erk since B-Raf is an upstream regulator of Erk activity. 
Figure 3. (A) Putative biological processes as ociated with target genes that can be negativ ly aff cted
by ectopic over-expression of miR-193a-3p and -5p, as i entified using DAVID analysis. (B–D) Ectopic
over-expression of miR-193a ar s reduces target genes in A375 (B), MeWo (C), and 501Mel (D).
The expression of direct targets of miR-193a-3p (KRAS, EBBB2, and MCL1) or -5p (PIK3R3, MTOR,
and NUSAP1) in melanoma cell lines following transfection with miR-193a-3p or -5p was measured by
RT-qPCR. Data are normalized to β-actin and control mimic-transfected cells. Data are representative
of three independent experiments ± SD performed in triplicate. Statistical analysis was performed
using Student’s t-test (* p < 0.5, ** p < 0.01, compared to the corresponding control.)
2.4. Ectopic Over-Expression of miR-193a Arms Inhibits Erk and Akt Signaling
Extracellular signal-regulated kinases (Erk) and Akt signaling are often aberrantly activated
in melanoma cells, inducing cell proliferation and survival. Therefore, we analyzed the ability of
miR-193a arms to modulate the protein expression level of B-Raf and the phosphorylation levels of Erk
1/2 and Akt 1/2/3.
Both miR-193a-3p and miR-193a-5p over-expression induced a significant decrease in B-Raf levels
and a decrease in phosphorylation of Akt 1/2/3 and Erk 1/2 proteins in all melanoma cell lines (Figure 4).
Noteworthily, miR-193a -3p and -5p decreased the phosphorylation of Erk 1/2 without altering
the total protein levels. The observed decrease of B-Raf protein is in line with the reduced activation of
Erk since B-Raf is an upstream regulator of Erk activity.
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over-expression of miR-193a-3p and miR-193a-5p in melanoma cells. Protein expression of B-Raf, 
p-Akt, p-Erk 1/2, total Erk 1/2, and β-actin in A375 (A), MeWo (B), and 501Mel (C) cell lines after 72 h 
of transfection with miRNA mimics was performed by Western blot analysis. Data are representative 
of three independent experiments ± SD performed in triplicate. One-way ANOVA followed by 
Dunnett’s multiple comparisons test was performed. * p < 0.05, ** p < 0.01, *** p < 0.001, compared to 
corresponding control. 
2.5. Ectopic Over-Expression of miR-193a Arms Induces Apoptosis 
The ability of miR-193a arms to induce apoptosis in human melanoma cells was investigated by 
evaluating the cleavage of poly (ADP-ribose) polymerase (PARP) and the internucleosomal DNA 
fragmentation, phenomena that occur during early [51] and late stages of programmed cell death, 
respectively. 
The results showed that both miR-193a arms produced two bands derived from PARP cleavage 
(116 and 89 kDa, respectively) in the melanoma cell lysates (Figure 5A). 
Figure 4. Ectopic over-expression of iR-193a ar s reduces Akt and Ekt pathways activation.
Protein expression levels of B-Raf, p-Akt, p-Erk 1/2, total Erk 1/2, andβ-actin after ectopic over-expression
of miR-193a-3p and miR-193a-5p in melanoma cells. Protein expression of B-Raf, p-Akt, p-Erk 1/2,
total Erk 1/2, and β-actin in A375 (A), MeWo (B), and 501Mel (C) cell lines after 72 h of transfection
with miRNA mimics was performed by Western blot analysis. Data are representative of three
independent experiments ± SD performed in triplicate. One-way ANOVA followed by Dunnett’s
multiple comparisons test was performed. * p < 0.05, ** p < 0.01, *** p < 0.001, compared to
corresponding control.
2.5. Ectopic Over-Expression of miR-193a Ar s Induces Apoptosis
The ability of miR-193a arms to induce apoptosis in human melanoma cells was investigated
by evaluating the cleavage of poly (ADP-ribose) polymerase (PARP) and the internucleosomal
DNA fragmentation, phenomena that occur during early [51] and late stages of programmed cell
death, respectively.
The results showed that both miR-193a arms produced two bands derived from PARP cleavage
(116 and 89 kDa, respectively) in the melanoma cell lysates (Figure 5A). The pro-apoptotic effect
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of miR-193a was confirmed also by the internucleosomal DNA fragmentation analysis. Indeed, a
significant accumulation of DNA-histone fragments (almost threefold increase) in the cytoplasmic
fraction of all three cell lines compared to the respective controls was observed after miR-193a arm
ectopic over-expression (Figure 5B).
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Figure 5. Ectopic over-expression of miR-193a arms induces apoptosis. PARP cleavage (A) and
internucleosomal DNA fragmentation (B) in A375, Me o, and 501Mel cell lines after 72 h of ectopic
over-expression of miR-193a-3p and miR-193a-5p. ata are presented as means ± SD of three
independent experiments performed in triplicate. Ordinary one-way ANOVA followed by Dunnett’s
multiple comparisons test was performed, ** p< 0.01; *** p< 0.001 compared to the corresponding co trol.
2.6. miR-193a-5p Does Not Repress TROY Expression
To explore the molecular mechanisms involved in miR-193a-5p anti-melanoma activity, its
capability to repress TROY mRNA was evaluated because TROY is a predicted (by TargetScan 7.2,
Table S2) and not yet validated direct target of miR-193a-5p.
TROY, called also TAJ or TNFRSF19 [52,53], is a gene encoding an orphan member of the tumor
necrosis factor (TNF) receptor superfamily that is implicated in several cancers [54–56], including
melanoma [57] and can promote Akt pathway [56,58].
We observed that ectopic over-expression of miR-193a-5p induced a significant decrease
expression of TROY in the three cell lines (Figure 6A). To further investigate the effects miR-193a-5p,
we co-transfected miR-193a-5p mimic and luciferase reporter plasmid containing wt-Luc-TROY
(Figure S1). As shown in Figure 6B, the luciferase activity was not significantly repressed by
miR-193a-5p over-expression, suggesting that miR-193a-5p does not directly target TROY (Figure 6B).
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mRNA 3′-UTR interaction. Luciferase assay signal did not show any downregulation by 
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Figure 6. (A) Ectopic over-expression of miR-193a-5p reduces TROY transcriptional expression levels
in A375, MeWo, and 501Mel cells. Data are representative of three independent experiments ± SD
performed in triplicate. Statistical analysis was performed by Student’s t-test (** p < 0.01, *** p < 0.001,
compared to corresponding control). (B) Luciferase assay analysis for miR-193a-5p and TROY mRNA
3′-UTR interaction. Luciferase assay signal did not show any downregulation by miR-193a-5p compared
to the negative control.
3. Discussion
MiR-193a arms play a disease-dependent role of tumor suppressors or oncogenes, respectively
associated with their under-expression in several tumor types and over-expression in others [15,16].
This trend may seem controversial, but it can be explained by the correlation between the expression
of miRNAs and their target genes in different types of cells. Indeed, the biological effect of miRNA
depends on the expression of each single gene target, which may present different expressions in
different types of cancer cells [6,7].
For the first time, we showed that miR-193a-3p and miR-193a-5p act as tumor suppressors in
melanoma cells, and both are significantly down-expressed in plasma-exosomes of melanoma patients
compared to healthy controls.
Interestingly, the arm -3p was more expressed than the -5p in both healthy subjects and melanoma
patients indicating the absence of a miRNA-arm switching, i.e., the imbalance between the two
miR-193a arm expression. Evidence reported that the expression of the arm of some miRNAs can
change during cancer progression, accordingly with a different role played by single arm [26,59–62].
Therefore, our data showing a consistent balance of miR-193a arm expression in healthy subjects and
melanoma patients are consistent with the same role of tumor suppressor here reported of miR-193a-3p
and miR-193a-5p in melanoma cells.
The expression trend in exosomes from melanoma patients gave us great support in the hypothesis
of a tumor suppressor role of these miRNAs in melanoma. This role was investigated on cultured
melanoma cells. Independently from their primary or metastatic origin, melanoma cells decreased
their viability when transfected with miRNA-193a, -3p or -5p. Bioinformatics tools and the analysis of
cell expression of validated mRNA-targets for miR-193a arms revealed that the two miR-193a arms
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may induce a similar effect on cell viability modulating common pathways, although not targeting
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In detail, a strong down-modulation of several cancer l ictly involved in melanoma
development and progression was observed following ectopic over-expr ssion of miR-193a, including
pro-proliferative m lecules and anti-apoptotic f ct rs, previously validated as irect targets of
miR-193a [41,42,63–66]. In particular, they strongly downregulated ERBB2, an epidermal growth factor
receptor (EGFR), targeted by both miR-193a arms [40,46,47]. This molecule is frequently over-expressed
in various cancers where it promotes an uncontrolled cellular proliferation by the activation of several
effectors [67]. Among these downstream effectors, there are other molecules targeted by miR-193a-3p or
miR-193a-5p: KRAS, a target of miR-193a-3p [45], and PIK3R3 and mTOR, targets of miR-193a-5p [21],
which are all proteins stimulating proliferation, cell cycle progression, and cell survival in cancer
cells [68,69]. Furthermore, the ectopic over-expression of each miR-193a arm induced a significant
decrease of anti-apoptotic factors. In detail, the expression of MCL-1, a member of the Bcl2 family
which promotes cell survival [70], was affected by miR-193a-3p [49,50], while miR-193a-5p decreased
the expression of NUSAP-1 [48], a microtubule-associated protein controlling cell proliferation by
governing spindle assembly, chromosome segregation, and cytokinesis, whose decrease leads to
apoptosis [71].
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Our results support the hypothesis that both miR-193a arms similarly modulate the same cellular
processes, i.e., cell proliferation and survival, through the regulation of the expression of differential,
but sometimes overlapped, specific mRNA targets.
Moreover, according to these observations, we found that both miR-193a arms significantly
decreased the activation of two cell pathways often aberrantly activated in melanoma promoting cell
proliferation and survival and inhibiting the apoptotic process: Erk and Akt signaling [72].
It is noteworthy that the ectopic over-expression of miR-193a induced a significant decrease in the
phosphorylation of these proteins without affecting their total expressions. The lower activation of
these pathways may be related to the ability of the miR-193a arms to directly modulate the expression
of corresponding up-stream molecules, such as ERBB2 [73], KRAS [74], and PIK3R3 [75].
The ability of miR-193a-5p to directly target ERBB2 also provides a possible explanation for the
observed decreased expression levels of TROY following ectopic over-expression of this arms. Indeed,
a strict interaction between ErbB2 and TROY was described in glioblastoma cells [58], where Ding and
colleagues reported a positive correlation of the expression levels of TROY and EGFRs, which promote
each other’s activity: TROY facilitates EGFR activation and delays EGFR internalization, while EGFRs
increase TROY-induced NF-κB activation.
Altogether, our findings strongly support the tumor suppressor role of miR-193a arms and suggest
their potential as therapeutic agents in melanoma through the modulation of several key pathways
involved in melanoma progression. Very recently, Ylösmäki and collaborators highlighted the ability
of miR-193a-3p to significantly downregulate the expression of programmed death-ligand 1 (PD-L1) in
B16.OVA murine melanoma model [76], suggesting its ability to reduce melanoma immune escape.
Their actions on cancer cells both by favoring apoptotic processes and reducing the expression of
PD-L1 make these miRNAs particularly promising as therapeutic agents in cutaneous melanoma.
Moreover, this reported pleiotropic action of miR-193a could have the advantage of overcoming
the mechanisms of resistance to target therapies due to the onset of modifications in intracellular
pathways and the activation of compensatory mechanisms. For instance, the pleiotropic ability to
modulate both Erk and Akt pathways, inducing a final anti-proliferative and pro-apoptotic effect,
could be advantageous in melanoma treatment. Several small-molecule inhibitors of the Erk or the
mTOR pathways have been developed, but clinical benefits are limited by the broad crosstalk between
these two pathways and the subsequent onset of drug resistance due to activation of intracellular
compensatory mechanisms following prolonged treatment [77,78]. Evidence supports the advantage
of Erk/Akt dual inhibitors [78,79]. In this context, the ability of miR-193a to target molecules, which are
involved in the regulation of both Erk and Akt pathways, can be promising.
Several miRNA mimics are tested in early phase clinical trials (NCT02580552; NCT03713320;
NCT03603431) [80,81], such as MesomiR 1 (ENGeneIC), a miRNA mimic that aims to replace miR-16,
a tumor suppressor that is reduced in malignant pleural mesothelioma. MesomiR 1 successfully
completed the phase I clinical trial and will soon start phase II [82]. Considering all the preclinical
and clinical studies on miRNAs, we can speculate that in the next decade, miRNA-based drugs could
improve the management of several diseases, including cancer. In this context, miR-193a may represent
an interesting candidate drug against melanoma and other cancers.
4. Materials and Methods
4.1. miRNA-193a Arms Evaluation in Plasma Exosomes
4.1.1. Enrollment of Patients and Healthy Volunteers and Sample Collection
Patient recruitment was carried out at the Department of Oncology of the University Hospital
of Pisa while healthy volunteers, with similar age and sex distribution, were recruited from the
Blood Donor Center of the University Hospital of Pisa. The current study was accepted by the Ethics
Committee of the Great North West Area of Tuscany (395/2014 to P.N.) and it was conducted in
accordance with the principles of the Declaration of Helsinki. Signed informed consent was obtained
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from each participant. Eleven AJCC stage IV (https://cancerstaging.org/) patients (Table 1) and eleven
healthy volunteers with similar age and sex distribution entered this study. In detail, 2.5 mL of blood
were drawn from each patient, collected in BD Vacutest Kima tubes containing EDTA, and centrifuged
at 4 ◦C for 10 min at 1900× g for 1 h. Plasma supernatant was then aliquoted into 1.5 mL DNA LoBind
tubes (Eppendorf AG, Hamburg, Germany) and stored at −80 ◦C until analysis. The timing of blood
collection from patients was within a month after histologically proven melanoma metastasis.
4.1.2. Expression Analysis of Plasma Exosome-Derived miRNAs
The isolation of exosome-derived miRNAs from plasma samples was performed using
ExoQuick-TCTM Exosome Precipitation Solution (Exiqon, Vedbaek, Denmark), according to the
manufacturer’s instructions. Briefly, 250 µL of plasma were centrifuged at 3000× g for 15 min. Then,
the supernatant was transferred to a new tube where Exoquick reagent was added in the appropriate
volume. After incubation at 4 ◦C for 30 min, samples were centrifuged at 1500× g for 30 min.
The obtained pellet was used for the extraction of miRNAs.
The miRNeasy Serum/Plasma Mini Kit (Qiagen, Hilden, Germany) was used for purification
and extraction of miRNAs from isolated exosomes, according to the manufacturer’s instructions.
The spike-in control, aCaenorhabditis elegansmiR-39 miRNA mimic (#219610, Qiagen, Hilden, Germany),
used as standard, was added in each sample during the purification, according to the manufacturer’s
instructions. Samples were retro-transcribed by the miScript Reverse Transcription II Kit (Qiagen,
Hilden, Germany) and the corresponding cDNA was diluted 1:3 in RNase-free water.
The miScript SYBR-Green PCR kit (Qiagen, Hilden, Germany) was used to perform quantitative
real-time PCR experiments, according to the manufacturer’s instructions, and the fluorescent signal
was detected on the MiniOpticon CFX 48 real-time PCR Detection System (Bio-Rad, Hercules, CA,
USA). MiScript Primer Assays specific for hsa-miR-193a-3p (MIMAT0000459) and hsa-miR-193a-5p
(MIMAT0004614) were obtained from Qiagen. The miRNA expression was calculated using the Ct
method and normalized to the expression of the spike-in control. Each experiment was performed
in triplicate.
4.2. Cell Lines
Human melanoma cells A375 (ATCC® CRL-1619, from primary cutaneous melanoma) and MeWo
(ATCC® HTB-65, from lymph node cutaneous melanoma metastasis) were obtained from the American
Type Culture Collection (ATCC). 501Mel (from cutaneous melanoma metastasis) were kindly provided
by Dr. Poliseno (Oncogenomics Unit, Core Research Laboratory, Istituto Toscano Tumori c/o IFC-CNR,
Pisa, Italy).
All cell lines were cultured in RPMI 1640 medium (Euroclone, Milan, Italy) supplemented with
10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin (Euroclone, Euroclone,
Milan, Italy) in a humidified atmosphere containing 5% CO2 at 37 ◦C. Cell morphology was examined
under light microscopy.
4.3. miRNA Mimics and Cell Transfection
miScript miRNA mimics of hsa-miR-193a-3p and hsa-miR-193a-5p were purchased from Qiagen
(Hilden, Germany). The mimic scramble was used as control (Ctrl) in each experiment. Cell lines were
plated at 60% of confluence and transfected with 10 nM mimic (miR-193a-3p or miR-193a-5p) or Ctrl
using Lipofectamine 2000® (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA), according to
the manufacturer’s protocol.
4.4. Cell Proliferation Assay
Cell proliferation was measured using the Neutral Red Assay (Sigma-Aldrich, Milan, Italy) as
previously reported [83]. Briefly, after 24 h from seeding melanoma cells (5 × 103 cells/well) onto
96 well plates, cells were transfected with 10 nM mimic or the control (Ctrl). After 72, 96, or 120 h, 10 µL
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of a neutral red solution (1% acetic acid and 50% ethanol) were added to each well, and cells were
incubated for 2 h at 37 ◦C. Optical density at 540 nm was measured using Infinite® M200 NanoQuant
instrument (Tecan, Salzburg, Austria).
4.5. Pathway Analysis
The predicted targets of human miR-193a-3p and -5p were obtained from the TargetScan database
(http://www.targetscan.org/faqs.Release_7.html). The predicted targets were pooled and uploaded
to Database for Annotation, Visualization, and Integrated Discovery (DAVID) (https://david.ncifcrf.
gov/) [84] to Gene Ontology (GO) analysis [85].
4.6. mRNA Expression Analyses
Total RNA from cells was extracted using the RNeasy Mini Kit and, then reverse transcribed
using the QuantiTect Reverse Transcription kit (Qiagen, Valencia, California, USA), according to
the manufacturer’s instructions. Real-time PCR was performed using SsoFast Eva Green Supermix
(Ref. 172–5201; Bio-Rad, Hercules, California, USA). The sequences of forward and reverse primers
were the following: ERBB2 (F) CCTCTGACGTCCATCATCTC and (R) ATCTTCTGCTGCCGTCGCTT;
K-RAS (F) CAGTAGACACAAAACAGGCTCAG and (R) TGTCGGATCTCCCTCACCAATG; TROY
(F) TGCTTGCCAGGATTTTATAGGAA and (R) GACGCGATCTTCACGAGGTT; PIK3R3 (F) CTTGCT
CTGTGGTGGCCGAT and (R) GACGTTGAGGGAGTCGTTGT; MTOR (F) ATGCAGCTGTCCTG
GTTCTC and (R) AATCAGACAGGCACGAAGGG; MCL-1 (F) CCAAGAAAGCTGCATCGAACCAT
and (R) CAGCACATTCCTGATGCCACCT; NUSAP1 (F) AGCCCATCAATAAGGGAGGG and
(R) ACCTGACACCCGTTTTAGCTG; β-actin (F) 5-AACTGGACGGTAGAAGGTGAC and (R)
5-GACTTCCTGTAACAACGCATC. The mRNA expression was calculated using the ∆∆Ct method.
4.7. Western Blot Analysis
The analysis of protein expression by Western blotting was performed as previously described [86].
The primary antibodies used and their dilutions were the followings: anti-p-Akt1-2-3 (sc-7985-R, Santa
Cruz Biotechnology), anti-ERK1 (p44)/ERK2 (p42) (Ref. sc-514302, Total ERK, Santa Cruz Biotechnology),
anti-Raf-B (Ref. sc-5284 Santa Cruz Biotechnology) at 1:200 dilution; anti-phosphotyrosine204-ERK1
(p44)/ERK2(p42) (Ref. sc-7383, Santa Cruz Biotechnology) at 1:500 dilution; anti-PARP) (Ref. 9542,
Cell Signaling Technology) and anti-β-actin (#MAB1501, Merck-Millipore, Burlington, MA, USA),
at 1:5000 dilution overnight at 4 ◦C. At room temperature, the membranes were incubated with
horseradish peroxidase (HRP)-labeled secondary anti-rabbit (#MAB201P, Merck-Millipore, Burlington,
MA, USA) or anti-mouse antibodies (A4416, Sigma-Aldrich, Milan, Italy), for 2 h. Detection of
chemiluminescence signals and densitometric analysis of blots were performed using ImageQuant
LAS 4000 (GE Healthcare) and ImageLab software (Bio-Rad), respectively.
4.8. Cell Death Detection ELISA Plus
The cytoplasmic levels of histone-associated DNA fragments (mono- and oligo-nucleosomes),
a marker of the apoptotic process, were investigated using the Cell Death Detection ELISA plus
(#11774425001, Sigma-Aldrich, Milan, Italy), as previously reported by Carpi and colleagues [83].
4.9. Luciferase Assay
The segments of the wild-type 3′UTRs of the gene of interest (TROY) containing predicted target
sites of miR-193a-5p were cloned into the pmirGLO dual-luciferase reporter (Promega, Madison,
WI, USA) (Figure 6A) (wt-Luc-TROY). The pmirGLO Vector was linearized with the DraI and XbaI
restriction enzymes to generate overhangs that are complementary to the annealed oligonucleotide,
which was ligated by T4 DNA ligase. Sequences of primers: TROY_top_1 AAACTATAGTAAGACCCAT,
TROY_bottom_1 CTAGATGGGTCTTACTATAGTTT, TROY_seq_F TTACAACCGCCAAGAAGCTG,
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TROY_seq-R AAAACCTCCCACATCTCCCC. Constructs were transformed using One Shot™ Stbl3™
competent cells and the purified plasmid DNA was directly transfected into Hek294T cells.
Firefly luciferase was used as the primary reporter for miRNA regulation of the 3′UTR.
Renilla luciferase was used as an internal control for normalization. HEK 293T cells were maintained
in 96-well plates and co-transfected with luciferase reporters (1.2µg/well) and oligo (15 or 50 nm
of miR-193a-5p mimic or negative control). The first luciferase signal reports specific experimental
conditions, and the second signal reflects transfection efficiency and cell viability.
Luciferase activities were measured after 72 h using the Dual-Glo Luciferase Assay System
(Promega) following the manufacturer’s protocol. Firefly luciferase activity was normalized to sea
pansy luciferase activity.
4.10. Statistical Analysis
Graphic representation and statistical analysis of data were performed using GraphPad Prism 7.0
(GraphPad Software, San Diego, CA, USA). Student’s t-test and one-way ANOVA with Dunnett’s
multiple comparison test were used for comparison of two or more than two groups, respectively.
Data are presented as mean ± standard deviation (SD) of three independent experiments performed
in triplicate.
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miRNAs microRNAs
hsa Homo sapiens
KRAS Kirsten rat sarcoma viral oncogene homolog
ERBB2 Erb-B2 receptor tyrosine kinase 2
PIK3R3 Phosphoinositide-3-kinase regulatory subunit 3
mTOR Mammalian target of rapamycin
MCL1 Myeloid leukemia cell differentiation
NUSAP1 Nucleolar and spindle associated protein 1
FBS Fetal bovine serum
ATCC American Type Culture Collection
Ctrl Control
DAVID Database for Annotation, Visualization, and Integrated Discovery
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MAPK Mitogen-activated protein kinase
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Erk Extracellular signal-regulated kinases
PARP Poly ADP ribose polymerase
EGFR Epidermal growth factor receptor
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PD-L1 Programmed death-ligand 1
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